Time metrics, treatment and complications of the participants
| Characteristics | Total (n=171) | TXA (n=89) | Placebo (n=82) | P value |
| Time intervals, median (IQR), min | ||||
| Onset to door | 120.0 (69.0–190.0) | 120.0 (77.0–184.0) | 120.0 (66.0–190.0) | 0.76 |
| Onset to treatment | 290.0 (185.0–370.0) | 290.0 (205.0–369.0) | 285.0 (180.0–378.0) | 0.87 |
| Imaging to treatment | 107.5 (73.0–161.0) | 128.0 (67.0–172.0) | 103.0 (74.0–160.0) | 0.40 |
| BP during TXA (Placebo) mean±SD, mm Hg | ||||
| SBPmax | 170.3±24.3 | 170.1±24.8 | 170.4±23.8 | 0.95 |
| DBPmax | 100.5±16.0 | 99.5±13.8 | 101.5±18.0 | 0.48 |
| MAPmax | 123.3±17.7 | 122.8±16.4 | 123.9±19.0 | 0.70 |
| Concomitant therapy during hospitalisation, n (%) | ||||
| Antihypertensive therapy | 142 (83.0) | 77 (86.5) | 65 (79.3) | 0.21 |
| Osmotic therapy | 125 (73.1) | 67 (75.3) | 58 (70.7) | 0.50 |
| Statin therapy | 11 (6.4) | 7 (7.9) | 4 (4.9) | 0.43 |
| Surgical intervention during hospitalisation, n (%) | ||||
| Evacuation of intracranial haematoma | 29 (17.0) | 16 (18.0) | 13 (15.9) | 0.71 |
| Decompressive craniectomy | 2 (1.2) | 1 (1.1) | 1 (1.2) | 0.95 |
| EVD | 3 (1.8) | 2 (2.2) | 1 (1.2) | 0.61 |
| DVT prophylaxis, n (%) | ||||
| Anticoagulation | 16 (9.4) | 11 (12.4) | 5 (6.1) | 0.16 |
| Compression | 51 (29.8) | 31 (34.8) | 20 (24.4) | 0.14 |
| Complications, n(%) | ||||
| Epilepsy | 1 (0.6) | 1 (1.2) | 0.30 | |
| Pulmonary infection | 36 (21.1) | 20 (22.5) | 16 (19.5) | 0.64 |
| Gastrointestinal bleeding | 17 (9.9) | 9 (10.1) | 8 (9.8) | 0.94 |
| DVT | 13 (7.6) | 8 (9.0) | 5 (6.1) | 0.48 |
P value for comparison between patients with TXA and placebo.
BP, blood pressure; DBP, diastolic blood pressure; DVT, deep venous thrombosis; EVD, external ventricular drain; MAP, mean arterial pressure; SBP, systolic blood pressure; TXA, tranexamic acid.